Loading...
Publication
Indústria Farmacêutica Portuguesa e a Medicina Personalizada: um estudo prospetivo
| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 3.23 MB | Adobe PDF |
Authors
Advisor(s)
Abstract(s)
“O medicamento certo, para o paciente certo, na altura certa”. A Medicina Personalizada
tem vindo a apresentar-se como solução para inúmeras condições de saúde. Muitas das terapias
personalizadas têm vindo a ser desenvolvidas por empresas farmacêuticas um pouco por todo
o mundo, e gradualmente começam a ganhar espaço não apenas nos mercados, mas também
como potencial passo evolutivo da medicina.
Sobre esta premissa, e sobre a vontade de compreender a que distância se encontra o
mercado português destas novas terapias emergentes, desenvolveu-se um estudo prospetivo de
forma a avaliar a situação da Medicina Personalizada junto da Indústria Farmacêutica
Portuguesa.
Recorrendo ao Método Delphi, reuniu-se um painel de especialistas, líderes e
responsáveis de empresas ou outras entidades relacionadas com o setor farmacêutico, em jeito
de obter opiniões e consensos sobre o futuro da indústria face às novas terapias personalizadas.
O método envolveu uma primeira ronda de questionários online, seguida por uma segunda
ronda composta por questionários criados individualmente para cada especialista.
Ao final das duas rondas concluiu-se que as áreas da Farmacogenómica, Digital Health,
Inteligência Artificial e Terapias Genéticos são reconhecidas pelos especialistas como áreas de
grande importância no campo da saúde, e que devem merecer a melhor atenção e foco das
empresas farmacêuticas. Contudo, foi também consensual que a implementação destas novas
terapias em Portugal não será alcançada num curto espaço de tempo ou, de forma decisiva, pela
iniciativa e investimento do tecido empresarial Português.
“The right medicine, for the right patient, at the right time”. Personalized Medicine has been presenting itself as a solution for countless health conditions. Many personalized therapies have been developed by pharmaceutical companies all over the world, and gradually begin to gain space not only in the markets, but also as a potential evolutionary step in medicine. Based on this premise, and on the desire to understand how far the Portuguese market is from these new emerging therapies, a prospective study was developed to assess the situation of Personalized Medicine on the Portuguese Pharmaceutical Industry.” Using the Delphi Method, a panel of experts, leaders and heads of companies or other entities related to the pharmaceutical sector was brought together in order to obtain opinions and consensus on the future of the industry considering the new personalized therapies. The method involved a first round of online questionnaires, followed by a second round consisting of questionnaires created individually for each expert. At the end of the two rounds, it was concluded that the areas of Pharmacogenomics, Digital Health, Artificial Intelligence and Genetic Therapies are recognized by specialists as areas of great importance in the field of health, and that they should deserve the best attention and focus from pharmaceutical companies. However, it was also agreed that the implementation of these new therapies in Portugal will not be achieved in a short period of time or, decisively, by the initiative and investment of Portuguese companies.
“The right medicine, for the right patient, at the right time”. Personalized Medicine has been presenting itself as a solution for countless health conditions. Many personalized therapies have been developed by pharmaceutical companies all over the world, and gradually begin to gain space not only in the markets, but also as a potential evolutionary step in medicine. Based on this premise, and on the desire to understand how far the Portuguese market is from these new emerging therapies, a prospective study was developed to assess the situation of Personalized Medicine on the Portuguese Pharmaceutical Industry.” Using the Delphi Method, a panel of experts, leaders and heads of companies or other entities related to the pharmaceutical sector was brought together in order to obtain opinions and consensus on the future of the industry considering the new personalized therapies. The method involved a first round of online questionnaires, followed by a second round consisting of questionnaires created individually for each expert. At the end of the two rounds, it was concluded that the areas of Pharmacogenomics, Digital Health, Artificial Intelligence and Genetic Therapies are recognized by specialists as areas of great importance in the field of health, and that they should deserve the best attention and focus from pharmaceutical companies. However, it was also agreed that the implementation of these new therapies in Portugal will not be achieved in a short period of time or, decisively, by the initiative and investment of Portuguese companies.
Description
Keywords
Indústria farmacêutica Medicina Personalizada Método Delphi